Our research aims to analyze the levels of NfL, GFAP, FGF-21, GDF-15 in both CMT patients and control subjects to determine the feasibility of using these biomarkers as an indicator of the severity of CMT and to assess the reliability of these biomarkers for future studies. This evidence concerns the gene FGF21 and Charcot-Marie-Tooth disease.